Israel B F, Pickles R J, Segal D M, Gerard R D, Kenney S C
Division of Infectious Diseases, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
J Virol. 2001 Jun;75(11):5215-21. doi: 10.1128/JVI.75.11.5215-5221.2001.
Although many recombinant adenovirus vectors (rAd) have been developed, especially by using group C adenoviruses, to transfer and express genes, such rAd do not readily infect B-cell lines due to the lack of the coxsackievirus-adenovirus receptor. Bispecific antibodies have been used in different cell systems to facilitate entry of rAd into otherwise nonpermissive cells. Bispecific antibody is synthesized by covalently linking two monoclonal antibodies with distinct specificities. It has been shown that lymphoproliferative tumors commonly express the cell surface protein CD70, while this receptor is normally expressed on only a small subset of highly activated B cells and T cells. We therefore investigated whether a bispecific antibody with specificities for the adenovirus fiber protein and CD70 can facilitate rAd entry and subsequent expression of rAd-encoded genes in CD70-positive B cells. We found high CD70 expression on Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), as well as some, but not all, Burkitt lymphoma (BL) lines. We show here that rAd encoding green fluorescent protein (Ad-GFP) infects EBV-transformed LCLs and a CD70-positive BL line 10- to 20-fold more efficiently in the presence of the CD70-fiber bispecific antibody. In contrast, the bispecific antibody does not enhance Ad-GFP infection in CD70-deficient BL cells. Using the CD70-fiber bispecific antibody, we increased the ability of rAd vectors encoding the EBV immediate-early proteins BZLF1 and BRLF1 to induce the lytic form of EBV infection in LCLs. These results indicate that the CD70-fiber bispecific antibody can enhance rAd infection of CD70-positive B cells and suggest the use of this vector to explore EBV-positive LCLs.
尽管已经开发出许多重组腺病毒载体(rAd),尤其是通过使用C组腺病毒来转移和表达基因,但由于缺乏柯萨奇病毒-腺病毒受体,此类rAd不易感染B细胞系。双特异性抗体已用于不同的细胞系统,以促进rAd进入原本不允许其进入的细胞。双特异性抗体是通过将两种具有不同特异性的单克隆抗体共价连接而合成的。研究表明,淋巴增殖性肿瘤通常表达细胞表面蛋白CD70,而该受体通常仅在一小部分高度活化的B细胞和T细胞上表达。因此,我们研究了一种对腺病毒纤维蛋白和CD70具有特异性的双特异性抗体是否能够促进rAd进入CD70阳性B细胞并随后表达rAd编码的基因。我们发现,爱泼斯坦-巴尔病毒(EBV)转化的淋巴母细胞系(LCL)以及一些(但不是全部)伯基特淋巴瘤(BL)细胞系上有高CD70表达。我们在此表明,在存在CD70-纤维双特异性抗体的情况下,编码绿色荧光蛋白的rAd(Ad-GFP)感染EBV转化LCL和CD70阳性BL细胞系的效率要高10至20倍。相比之下,双特异性抗体不会增强Ad-GFP对缺乏CD70的BL细胞的感染。使用CD70-纤维双特异性抗体,我们提高了编码EBV立即早期蛋白BZLF1和BRLF1的rAd载体在LCL中诱导EBV感染裂解形式的能力。这些结果表明,CD70-纤维双特异性抗体可以增强rAd对CD70阳性B细胞的感染,并提示使用该载体探索EBV阳性LCL。